This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The prolonged slowdown in biotechnology startup funding has given an opportunity for a specific set of investors to step in: corporate venture firms. Data compiled by BioPharma Dive show that venture funds associated with Novo Holdings, Eli Lilly and Sanofi have been among the most active backers of privately held companies this year. Novo Holdings, for exampl ...